Jeffrey R. Spencer, Ph.D., Founder and Chief
Spencer brings more than 20 years of experience in small molecule drug
discovery and development to STATegics, Inc., focusing on novel treatments for
rare and neuromuscular diseases, including Friedreich’s ataxia. Dr. Spencer
founded STATegics to advance the therapeutic and commercial potential of innovative
small molecules targeting cytokine receptors.
Based on STATegics’ discoveries, he has raised seed capital to support research
through several small business and preclinical development grant awards from
the government and private foundations. Prior
to STATegics, Dr. Spencer led Discovery Medicinal Chemistry at Celera Genomics
in South San Francisco, CA, overseeing preclinical programs in inflammatory
conditions and cancer. He held several positions of increasing responsibility
and supported screening-to-development programs including a novel treatment for
cancer (Abexinostat). Dr. Spencer
received a Ph.D. in organic chemistry at the University of California at San
Diego and conducted postdoctoral studies at the California Institute of
James L. Miller, Ph.D., Director of Biology
James L. Miller is a trained neuroscientist with over 25 years of research
and drug discovery experience, focusing on innovative approaches to treat diseases
of the central nervous system including Friedreich's Ataxia, traumatic brain
injury, Alzheimer's disease, neuropathic pain, and autoimmune-disease. Prior to
joining STATegics in 2011, Dr. Miller ledin
vitropharmacology at Elan Pharmaceuticals supporting lead discovery and
optimization for multiple programs within pain, Alzheimer’s and autoimmune therapeutic
areas. While at Neurex Corporation, he participated in the preclinical
development of Prialt® (ziconotide), a first-in-class N-type calcium channel
antagonist for the treatment of neuropathic pain. More recently, Dr. Miller supported preclinical
development of TI-001, an intranasal formulation of oxytocin for treatment of
high frequency episodic migraine and chronic migraine, currently in phase 2. Dr.
Miller received his post-doctoral training in neuroscience and physiology at
the UCSF Medical Center in San Francisco.
He is Principal Investigator of a small business grant awarded to
STATegics by the National Institutes of Health.